Apogee Therapeutics (APGE) Total Liabilities (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Total Liabilities data on file, last reported at $37.9 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $37.9 million, down 7.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $37.9 million (down 7.2% YoY), and the FY2025 annual result was $33.3 million, down 10.51% from the prior year.
• Total Liabilities grew to $37.9 million in Q1 2026 per APGE's latest filing, from $33.3 million in the prior quarter.
• Over five years, Total Liabilities peaked at $46.6 million in Q1 2023 and troughed at $4.4 million in Q2 2022.
• A 5-year average of $28.7 million and a median of $30.1 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2023 and 2024: Total Liabilities jumped 297.36% in 2023, then sank 52.45% in 2024.
• A 5-year view of Total Liabilities shows it stood at $10.0 million in 2022, then soared by 115.34% to $21.5 million in 2023, then soared by 72.9% to $37.2 million in 2024, then slipped by 10.51% to $33.3 million in 2025, then advanced by 13.86% to $37.9 million in 2026.
• Business Quant data shows APGE's Total Liabilities at $37.9 million in Q1 2026, $33.3 million in Q4 2025, and $39.8 million in Q3 2025.